Gallop Oncology

Executive Summary

Gallop Oncology is a clinical-stage biopharmaceutical company pioneering a novel immunotherapy approach targeting galectin-9, a key immunosuppressive protein in the tumor microenvironment. Its lead candidate, LYT-200, is a monoclonal antibody designed to directly kill tumor cells and reactivate anti-tumor immunity. The company is advancing LYT-200 in Phase 1/2 trials for hematologic malignancies and solid tumors. Founded in 2020 and based in Cambridge, MA, Gallop represents a promising approach in the immuno-oncology space, addressing a novel target with potential to overcome resistance to existing therapies. With early clinical data expected in the near term, the company is positioned to provide proof-of-concept for galectin-9 blockade and potentially attract partnership interest from larger biopharma. However, as a private, early-stage company with no disclosed financing or valuation, the risk profile remains high, and the trajectory depends on successful clinical readouts and capital access.

Upcoming Catalysts (preview)

• Q4 2026Initial Phase 1/2 safety and efficacy data for LYT-200 in hematologic malignancies40% success
• Q1 2027First patient dosed in solid tumor expansion cohort70% success
• TBDPotential partnership or licensing deal for LYT-20030% success